Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.

US-based biopharmaceutical company Arrakis Therapeutics closed a $75m series B round on Thursday with participation from spinout-focused investment fund Osage University Partners (OUP).
VenBio Partners and Nextech Invest co-led the round, which also featured GV, an early-stage corporate venturing subsidiary of diversified conglomerate Alphabet, and WuXi AppTec Venture Fund, an investment unit of pharmaceutical firm WuXi AppTec.
Alexandria Venture Investments, a corporate venturing arm of life science real estate provider Alexandria Real Estate Equities, also took part, as…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in